Is Your Thyroid Medication Part of the 2026 FDA Recall?
Only if your bottle is Vitruvias Thyroid Tablets USP 30 mg, lot 504950. Any other lot, any other brand, or any synthetic levothyroxine is untouched. The twist is that these tablets may be too strong, not too weak, so the risk is drug-induced hyperthyroidism rather than the more familiar undertreatment. Don't stop the pill on your own. Call your prescriber the same day for a replacement, and watch for a racing heart, tremor, or unexplained weight loss in the meantime.
On September 22, 2026, the FDA upgraded Vitruvias Therapeutics' recall of one lot of Thyroid Tablets USP 30 mg to Class I, its most serious tier, used when a defect carries a reasonable probability of serious harm or death. The scope is narrow: lot 504950, NDC 69680-166-00, expiration September 30, 2026, distributed between January 31 and September 30, 2025. About 3,655 units shipped and 1,955 sold. Vitruvias pulled the lot voluntarily on August 21 after testing suggested the tablets could be super-potent, meaning they may deliver more thyroid hormone than the label states.
How to tell if it's your bottle
Everything you need is on the label. If any single detail below doesn't match, this recall isn't yours.
| Detail | What to check for |
|---|---|
| Product name | Vitruvias Thyroid Tablets USP |
| Strength | 30 mg |
| Lot number | 504950 |
| NDC | 69680-166-00 |
| Expiration date | 9/30/2026 |
| Distribution window | Shipped between 1/31/2025 and 9/30/2025 |
| Manufacturer contact | safety@vitruvias.com or (256) 239-9373, Monday to Friday, 9 a.m. to 5 p.m. Central |
| If it matches your bottle | Call your prescriber today for a replacement. Do not stop the medication on your own. |
Any other lot, any other strength, any other brand, or any synthetic levothyroxine such as Synthroid, Levoxyl, or the generics is unaffected. The action targets this one bottle of natural desiccated porcine thyroid at this one strength.
Why the risk here runs hot, not cold
Most thyroid recalls in recent memory involved the opposite problem: underpowered tablets that left people quietly hypothyroid. This one is the mirror image. Vitruvias Thyroid Tablets USP is a natural desiccated porcine product that carries both thyroxine (T4) and triiodothyronine (T3). A super-potent tablet pushes hormone levels above normal and tips a person toward thyrotoxicosis rather than sluggishness.
So the warning signs run hot. The FDA and Vitruvias flag weight loss, heat intolerance, fatigue that feels wired rather than dulled, nervousness or new anxiety, muscle weakness, tremor, hypertension, chest pain, a racing heart, and heart rhythm disturbances. If you've been taking pills from lot 504950 and any of these have appeared or worsened in the past few months, that's the pattern to bring to your prescriber.
Why stopping the pill on your own is the wrong move
The reflex when a drug is recalled is to stop it. Both the FDA and Vitruvias explicitly say not to here. Thyroid hormone replacement isn't a symptomatic medicine you can pause. T4 has a half-life of about seven days, so blood levels fall gradually and biochemical hypothyroidism generally emerges over four to six weeks off treatment. A desiccated product also contains T3, which clears in about a day and can bring hypothyroid symptoms back sooner. In pregnancy the case against stopping is sharper still: undertreated maternal hypothyroidism is tied to higher rates of miscarriage, preterm birth, and impaired fetal neurodevelopment. Call the same day for a replacement prescription from a different lot or manufacturer, not a self-directed pause.
Who has the most to lose
The manufacturer specifically names elderly patients, pregnant women, and infants as highest-risk, particularly with prolonged exposure. An older heart handles a sudden thyroid excess less gracefully. Sustained excess hormone can trigger atrial fibrillation and destabilize coronary disease, and in pregnancy it can affect fetal development. If you fit one of these groups and your bottle matches, treat this as urgent rather than routine. Some symptoms warrant emergency care, not a phone call: severe chest pain, a sustained racing or irregular heartbeat, breathlessness, or the confusion, fever, and agitation that mark thyroid storm.
The order of operations if it's your bottle
- Check the label against the table above. Only lot 504950 at 30 mg is affected.
- Call your prescriber today. Ask for a replacement prescription for a different lot or an equivalent product, and mention any hyperthyroid symptoms you've noticed.
- Return the recalled bottle to the pharmacy where it was dispensed.
- Contact Vitruvias with questions at safety@vitruvias.com or (256) 239-9373, Monday to Friday, 9 a.m. to 5 p.m. Central.
- Recheck your TSH about six to eight weeks after switching, the standard interval for a levothyroxine-based regimen to reach a new steady state, so you know the new bottle is dosing you correctly.
- Report any adverse events to the FDA MedWatch program.
Where this stands
As of the August 24 press release, no adverse events had been reported to Vitruvias. A Class I designation is a preventive threshold, not a tally of harm already done. What would change the picture is a cluster of confirmed events tied to this lot, an expansion to other Vitruvias lots or other desiccated thyroid manufacturers, or an updated FDA notice with different symptom thresholds. For now the event is narrow and the fix is specific. If the bottle in your cabinet matches, act today. If it doesn't, none of this is yours.